[On the significance of mycotic pyelonephritis developing during tuberculostatic therapy].
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002175:Candida / Q000302:isolation & purification; D005260:Female; D005847:Geotrichosis; D006651:Histocytochemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology*; D009392:Nephrectomy; D011704:Pyelonephritis / Q000209:etiology*; D011776:Pyuria; D014394:Tuberculosis, Osteoarticular / Q000188:drug therapy; D014401:Tuberculosis, Urogenital / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents
Uber die Bedeutung der sich während tuberkulostatischer Therapie entwickelnden mykotischen Pyelonephritis.